We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+25.81%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$241M
AUM Growth
+$50.3M
Cap. Flow
+$11.8M
Cap. Flow %
4.88%
Top 10 Hldgs %
9.37%
Holding
372
New
47
Increased
146
Reduced
160
Closed
17

Top Buys

Rank Stock Value
1
BEPC icon
Brookfield Renewable
BEPC
+$1.51M
2
WES icon
Western Midstream Partners
WES
+$926K
3
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
+$707K
4
DK icon
Delek US
DK
+$681K
5
CVI icon
CVR Energy
CVI
+$669K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$1.61M
2
AIMT
Aimmune Therapeutics
AIMT
+$1.13M
3
AIV
Aimco
AIV
+$1.1M
4
VIV icon
Telefônica Brasil
VIV
+$1.01M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$988K

Sector Composition

Rank Sector Weight
1 Healthcare 29.53%
2 Real Estate 18.96%
3 Energy 16.61%
4 Materials 11.31%
5 Utilities 7.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
301
Replimune Group
REPL
$455M
$258K 0.11%
+6,769
New +$282K
VVR icon
302
Invesco Senior Income Trust
VVR
$456M
$258K 0.11%
64,827
-10,973
-14% -$41.3K
AGEN
303
Agenus
AGEN
$276M
$256K 0.11%
4,096
-404
-9% -$30K
RPTX
304
DELISTED
Repare Therapeutics
RPTX
$256K 0.11%
+7,469
New +$223K
RUBY
305
DELISTED
Rubius Therapeutics, Inc
RUBY
$256K 0.11%
33,793
-17,070
-34% -$101K
DVAX
306
DELISTED
Dynavax Technologies
DVAX
$254K 0.11%
57,062
+3,078
+6% +$13.9K
NVAX icon
307
Novavax
NVAX
$1.21B
$254K 0.11%
2,275
-4,491
-66% -$477K
BGT icon
308
BlackRock Floating Rate Income Trust
BGT
$321M
$253K 0.11%
21,455
-2,514
-10% -$29.2K
PHD
309
DELISTED
Pioneer Floating Rate Fund
PHD
$253K 0.11%
24,790
-5,042
-17% -$52.4K
BLW icon
310
BlackRock Limited Duration Income Trust
BLW
$490M
$252K 0.1%
15,840
-1,140
-7% -$17.4K
WVE icon
311
Wave Life Sciences
WVE
$1.12B
$252K 0.1%
32,032
+16
+0% +$134
INO icon
312
Inovio Pharmaceuticals
INO
$85.6M
$251K 0.1%
+2,362
New +$314K
VYGR icon
313
Voyager Therapeutics
VYGR
$181M
$251K 0.1%
35,079
+9,668
+38% +$92.9K
KYNB
314
Kyntra Bio
KYNB
$27.4M
$249K 0.1%
269
-54
-17% -$56.8K
VKTX icon
315
Viking Therapeutics
VKTX
$3.88B
$248K 0.1%
43,966
+1,459
+3% +$8.84K
ATRA icon
316
Atara Biotherapeutics
ATRA
$72.6M
$247K 0.1%
503
-811
-62% -$374K
CTMX icon
317
CytomX Therapeutics
CTMX
$690M
$245K 0.1%
37,343
-1,378
-4% -$9.84K
AFMD
318
DELISTED
Affimed
AFMD
$244K 0.1%
+4,197
New +$198K
PLRX icon
319
Pliant Therapeutics
PLRX
$65M
$244K 0.1%
+10,759
New +$270K
XBIT icon
320
XBiotech
XBIT
$68.6M
$244K 0.1%
15,584
-7,592
-33% -$140K
CVM icon
321
CEL-SCI Corp
CVM
$19.9M
$243K 0.1%
695
-100
-13% -$39.4K
VIR icon
322
Vir Biotechnology
VIR
$1.46B
$242K 0.1%
9,044
+43
+0.5% +$1.4K
EVF
323
Eaton Vance Senior Income Trust
EVF
$89.9M
$241K 0.1%
37,892
-5,238
-12% -$32.1K
TCRT icon
324
Alaunos Therapeutics
TCRT
$4.64M
$241K 0.1%
636
-25
-4% -$9.94K
RAPT
325
DELISTED
RAPT Therapeutics
RAPT
$240K 0.1%
1,519
-271
-15% -$58.9K
11 12
13
14 15

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2020 Portfolio in Review

As of Q4 2020, Virtus ETF Advisers held 372 positions worth $241M, up 26% from $191M the previous quarter. Its ten largest holdings account for 9.4% of the portfolio.

Virtus ETF Advisers deployed $11.8M of net new capital in Q4 2020, opening 47 new positions and adding to 146 existing holdings. Its largest new stake was Harmony Biosciences: 14,899 shares worth $539K.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 32% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $572K trimmed.

  • Virtus ETF Advisers's largest Q4 2020 buy was Harmony Biosciences: 14,899 shares worth $539K.
  • Virtus ETF Advisers added most to Brookfield Renewable in Q4 2020, an estimated $1.51M increase.
  • Virtus ETF Advisers's biggest Q4 2020 reduction was Amicus Therapeutics, cutting an estimated $572K.
  • Virtus ETF Advisers fully exited Immunomedics Inc in Q4 2020, selling an estimated $1.61M.
  • Virtus ETF Advisers's ten largest holdings make up 9.4% of its $241M portfolio in Q4 2020.
  • Virtus ETF Advisers opened 47 new positions and closed 17 in Q4 2020.
  • Virtus ETF Advisers's portfolio value rose 26% quarter-over-quarter to $241M.

Based on Virtus ETF Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.